Pharmaceutical Composition for Treating Covid-19 Comprising Otamixaban and at Least One of Camostat and Nafamostat

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a pharmaceutical composition for treating or preventing COVID-19, comprising the drug otamixaban (an anticoagulant) and at least one serine protease inhibitor, either camostat or nafamostat. The inventors discovered that combining otamixaban with very small amounts of camostat or nafamostat produces a strong synergistic antiviral effect against SARS-CoV-2, allowing otamixaban doses to be significantly reduced while improving efficacy.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of active COVID-19 infection to reduce viral load and disease severity.
• Prophylactic (preventive) use in high-risk populations (e.g., healthcare workers or immunocompromised patients) to prevent SARS-CoV-2 infection.
• Management of COVID-19 patients with complications such as blood clotting (thrombosis) due to the anticoagulant effect of otamixaban.
• Potential adaptation for other respiratory viruses that use similar host protease entry mechanisms.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers a new therapeutic combination that targets two different host mechanisms needed for viral entry, maximizing antiviral effect.
• Allows reduction of otamixaban dosage, potentially decreasing side effects while maintaining efficacy due to synergism with camostat/nafamostat.
• Otamixaban’s anticoagulant effect may also help manage COVID-19-related clotting complications, providing a dual-action benefit.
• Uses repurposed drugs with existing safety data, which may expedite regulatory approval for COVID-19 treatment.
• Formulation flexibility enables oral or injectable administration, adaptable to various clinical settings.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a pharmaceutical composition that is appropriate to treat or prevent SARS-CoV-2-related diseases such as COVID-19. The pharmaceutical composition comprises a pharmaceutically effective amount of i) otamixaban or a pharmaceutically acceptable salt thereof and ii) at least one of camostat, a pharmaceutically acceptable salt of camostat, nafamostat, and a pharmaceutically acceptable salt of nafamostat.